Last reviewed · How we verify
NCT02280161
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
trial testing cytology specimen collection procedure in Malignant Neoplasm in 2,000 participants. Currently enrolling.
16 September 2026
Quick facts
| Lead sponsor | Jonsson Comprehensive Cancer Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 16 September 2014 |
| Primary completion | 16 September 2026 |
| Estimated completion | 16 September 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- cytology specimen collection procedure
Conditions studied
- Malignant Neoplasm — all drugs for Malignant Neoplasm →
Sponsor
Jonsson Comprehensive Cancer Center — full company profile →
Who can join
18 and older, any sex, with Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research trial studies germ-line mutations in blood and saliva samples from patients with cancer. Studying samples of blood and saliva from patients with cancer in the laboratory may help doctors learn more about how inherited genetic mutations can affect cancer predisposition (an inherited increase in the risk of developing cancer), their impact on treatment response, and their role in cancer development.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.
Weidhaas J, Marco N, Scheffler AW, Kalbasi A, et al · · 2022 · cited 22× · PMID 35115362 · DOI 10.1136/jitc-2021-003625
Verify or expand the search:
- PubMed search for NCT02280161
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of cytology specimen collection procedure
Trials testing the same drug.
- NCT02132845 — Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer · NA · completed
- NCT02250404 — Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin · withdrawn
- NCT02273336 — Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer · completed
- NCT02250352 — Core Biopsies for Establishing a Breast Tumor Tissue Repository · recruiting
- NCT01987726 — Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors · completed
Other recruiting trials for Malignant Neoplasm
Currently open trials in the same condition.
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
- NCT07252739 — KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
- NCT07247110 — A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) · Phase 1 · recruiting
- NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting
Other Jonsson Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
- NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
- NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02280161 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
- Last refreshed: 10 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02280161.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing